Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

A pharmaceutical and a nonprofit are teaming up to evaluate segesterone acetate as a possible MS therapy to restore lost myelin in patients.

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...

A new study exposes the hidden bias behind delayed or denied treatments. It's time to break down these barriers and ensure everyone with #MS gets the care they deserve. ’ Therapeutic inertia ...

Patients receiving chemotherapy in Lincolnshire can now have additional treatment to help reduce their hair loss. Many cancer ...